180
Participants
Start Date
June 16, 2016
Primary Completion Date
April 21, 2022
Study Completion Date
April 21, 2022
Ranibizumab
1 intravitreal injection in both eyes on Day 1 (Baseline), with up to 2 re-treatments allowed for each eye if required
Novartis Investigative Site, Vienna
Novartis Investigative Site, Budapest
Novartis Investigative Site, Koebenhavn Ø
Novartis Investigative Site, Debrecen
Novartis Investigative Site, Bruges
Novartis Investigative Site, Ghent
Novartis Investigative Site, Zagreb
Novartis Investigative Site, Taipei
Novartis Investigative Site, Tallinn
Novartis Investigative Site, Riyadh
Novartis Investigative Site, Prague
Novartis Investigative Site, Marseille
Novartis Investigative Site, Rochester
Novartis Investigative Site, Praha 4 - Podoli
Novartis Investigative Site, Alexandria
Novartis Investigative Site, Baltimore
Novartis Investigative Site, Meselik
Novartis Investigative Site, Morgantown
Novartis Investigative Site, Hanover
Novartis Investigative Site, Taoyuan District
Novartis Investigative Site, Istanbul
Novartis Investigative Site, Louisville
Novartis Investigative Site, Ann Arbor
Novartis Investigative Site, Florence
Novartis Investigative Site, Kuala Lumpur
Novartis Investigative Site, Chicago
Novartis Investigative Site, Austin
Novartis Investigative Site, Aurora
Novartis Investigative Site, Amiens
Novartis Investigative Site, Kota Kinabalu
Novartis Investigative Site, Sacramento
Novartis Investigative Site, New Delhi
Novartis Investigative Site, Moscow
Novartis Investigative Site, Saint Petersburg
Novartis Investigative Site, Timișoara
Novartis Investigative Site, Ahmedabad
Novartis Investigative Site, Kazan'
Novartis Investigative Site, Cheboksary
Novartis Investigative Site, Brasov
Novartis Investigative Site, Madurai
Novartis Investigative Site, Coimbatore
Novartis Investigative Site, Vanchiyoor
Novartis Investigative Site, Graz
Novartis Investigative Site, Ostrava
Novartis Investigative Site, Ampelokipoi
Novartis Investigative Site, Athens
Novartis Investigative Site, Thessaloniki
Novartis Investigative Site, Mumbai
Novartis Investigative Site, Perugia
Novartis Investigative Site, Fiumicino
Novartis Investigative Site, Roma
Novartis Investigative Site, Nagoya
Novartis Investigative Site, Nagoya
Novartis Investigative Site, Yachiyo
Novartis Investigative Site, Fukuoka
Novartis Investigative Site, Fukuoka
Novartis Investigative Site, Kurume
Novartis Investigative Site, Sapporo
Novartis Investigative Site, Zentsujichó
Novartis Investigative Site, Shimajiri-Gun
Novartis Investigative Site, Izumi
Novartis Investigative Site, Ohtsu-city
Novartis Investigative Site, Fuchū
Novartis Investigative Site, Ōta-ku
Novartis Investigative Site, Setagaya-ku
Novartis Investigative Site, Sumida-ku
Novartis Investigative Site, Toshima-ku
Novartis Investigative Site, Kaunas
Novartis Investigative Site, Bucharest
Novartis Investigative Site, Bratislava
Novartis Investigative Site, Soguksu / Antalya
Novartis Investigative Site, Manchester
Novartis Investigative Site, Portsmouth
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY